3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Brain Neoplasms
19
Neoplasm Metastasis
13
Lung Neoplasms
13
Pancreatic Neoplasms
11
Melanoma
10
Carcinoma, Renal Cell
9
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Prostatic Neoplasms
6
Neoplasms
6
Glioblastoma
6
Breast Neoplasms
6
Liver Neoplasms
5
Head and Neck Neoplasms
4
Glioma
3
Colorectal Neoplasms
3
Uveal Melanoma
2
Sarcoma
2
Mesothelioma
2
Gliosarcoma
2
Gastrointestinal Neoplasms
2
Cholangiocarcinoma
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor
1
Spinal Cord Compression
1
Secondary Malignant Neoplasm of Liver
1
Sarcoma, Ewing
1
Interventions
pembrolizumab
11
epacadostat
2
Paclitaxel
2
spartalizumab
1
ribociclib
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Gemcitabine
1
Docetaxel
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Axitinib
1
AZD 6244
1
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Radiosurgery
×
Clear all
NCT03924869
2025-12-11
KEYNOTE-867
Merck Sharp & Dohme LLC
Phase 3
Terminated
448 enrolled
24 charts